The durable result shows up between months three and six, which is also why we book the follow-up photo at week 12 and the second compare at week 24
Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells
ARADES trial: A first-in-man, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ODM-201 in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) [abstract]
cartsman June 15, 2024, 12:41pm 62 No evidence
The company completed a 24-week Phase 2b NATIVE clinical trial (ClinicalTrials.gov NCT03008070) and demonstrated that the higher dose used in this study (1200 mg per day) reduced by at least two points the steatosis activity fibrosis (SAF) score (SAF is a measure that combines the degree of hepatocellular inflammation and cellular ballooning) with no worsening of fibrosis (primary endpoint)
Stop taking it and the drug stops working